[go: up one dir, main page]

MX2019013561A - Compuestos de pirrolopiridina-anilina para el tratamiento de trastornos dermicos. - Google Patents

Compuestos de pirrolopiridina-anilina para el tratamiento de trastornos dermicos.

Info

Publication number
MX2019013561A
MX2019013561A MX2019013561A MX2019013561A MX2019013561A MX 2019013561 A MX2019013561 A MX 2019013561A MX 2019013561 A MX2019013561 A MX 2019013561A MX 2019013561 A MX2019013561 A MX 2019013561A MX 2019013561 A MX2019013561 A MX 2019013561A
Authority
MX
Mexico
Prior art keywords
treatment
pyrrolopyridine
compounds
aniline compounds
dermal disorders
Prior art date
Application number
MX2019013561A
Other languages
English (en)
Other versions
MX389965B (es
Inventor
John Kincaid
Matthew Duncton
Original Assignee
Nflection Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nflection Therapeutics Inc filed Critical Nflection Therapeutics Inc
Publication of MX2019013561A publication Critical patent/MX2019013561A/es
Publication of MX389965B publication Critical patent/MX389965B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Se proporcionan en la presente compuestos, composiciones farmacéuticas que comprenden los compuestos, métodos para preparar los compuestos y métodos de uso de los compuestos y composiciones en el tratamiento de enfermedades y trastornos en un sujeto donde el sujeto necesita de un inhibidor de MEK donde el Compuesto es de acuerdo con la Fórmula (I): (ver fórmula) donde X1, R1, R2, R2a, R3, R3a y R3b son como se describe en la presente.
MX2019013561A 2017-05-19 2018-05-18 Compuestos de pirrolopiridina-anilina para el tratamiento de trastornos dermicos MX389965B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762508997P 2017-05-19 2017-05-19
US201862663202P 2018-04-26 2018-04-26
PCT/US2018/033547 WO2018213810A1 (en) 2017-05-19 2018-05-18 Pyrrolopyridine-aniline compounds for treatment of dermal disorders

Publications (2)

Publication Number Publication Date
MX2019013561A true MX2019013561A (es) 2022-02-09
MX389965B MX389965B (es) 2025-03-20

Family

ID=62620966

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2019013561A MX389965B (es) 2017-05-19 2018-05-18 Compuestos de pirrolopiridina-anilina para el tratamiento de trastornos dermicos
MX2022001697A MX2022001697A (es) 2017-05-19 2019-11-13 Compuestos de pirrolopiridina-anilina para el tratamiento de trastornos dermicos.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2022001697A MX2022001697A (es) 2017-05-19 2019-11-13 Compuestos de pirrolopiridina-anilina para el tratamiento de trastornos dermicos.

Country Status (16)

Country Link
US (3) US11161845B2 (es)
EP (1) EP3624796B1 (es)
JP (1) JP7212956B2 (es)
KR (1) KR102642411B1 (es)
CN (1) CN111065393B (es)
AU (1) AU2018270295B2 (es)
CA (1) CA3063536A1 (es)
DK (1) DK3624796T3 (es)
ES (1) ES3030506T3 (es)
FI (1) FI3624796T3 (es)
IL (1) IL270752B (es)
MA (1) MA49141A (es)
MX (2) MX389965B (es)
PL (1) PL3624796T3 (es)
PT (1) PT3624796T (es)
WO (1) WO2018213810A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10988483B2 (en) 2017-05-19 2021-04-27 Nflection Therapeutics, Inc. Fused heteroaromatic-aniline compounds for treatment of dermal disorders
EP3624796B1 (en) 2017-05-19 2025-03-19 NFlection Therapeutics, Inc. Pyrrolopyridine-aniline compounds for treatment of dermal disorders
MA55148A (fr) * 2018-11-20 2021-09-29 Nflection Therapeutics Inc Composés d'aryl-aniline et d'hétéroaryl-aniline pour le traitement de marques de naissance
CN113660931B (zh) * 2018-11-20 2024-10-11 恩福莱克逊治疗有限公司 用于治疗皮肤癌的芳基苯胺和杂芳基苯胺化合物
MA55141A (fr) 2018-11-20 2021-09-29 Nflection Therapeutics Inc Composés cyanoaryl-aniline pour le traitement d'affections de la peau
CA3120337A1 (en) 2018-11-20 2020-05-28 Nflection Therapeutics, Inc. Naphthyridinone-aniline compounds for treatment of dermal disorders
WO2020106305A1 (en) 2018-11-20 2020-05-28 Nflection Therapeutics, Inc. Thienyl-aniline compounds for treatment of dermal disorders
CA3193191A1 (en) * 2020-09-24 2022-03-31 Christopher Powala Treatment of cognitive dysfunction with pyrrolopyridine-aniline compounds
US20250179062A1 (en) * 2021-01-21 2025-06-05 Nflection Therapeutics, Inc. Crystalline forms of a pyrrolopyridine-aniline compound
JP2024503893A (ja) * 2021-01-21 2024-01-29 エヌフレクション セラピューティクス インコーポレイテッド ピロロピリジン－アニリン化合物を調製するための方法
CA3238962A1 (en) 2021-11-23 2023-06-01 Nflection Therapeutics, Inc. Formulations of pyrrolopyridine-aniline compounds
AU2022398467A1 (en) * 2021-11-23 2024-06-27 Nflection Therapeutics, Inc. Formulations of pyrrolopyridine-aniline compounds
PE20242178A1 (es) * 2022-03-17 2024-11-07 Springworks Therapeutics Inc Dosificacion no lineal de mirdametinib

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
KR890002631B1 (ko) 1984-10-04 1989-07-21 몬산토 캄파니 생물학적으로 활성인 소마토트로핀을 지속적으로 유리하는 조성물
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
PH30995A (en) 1989-07-07 1997-12-23 Novartis Inc Sustained release formulations of water soluble peptides.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
TW333456B (en) 1992-12-07 1998-06-11 Takeda Pharm Ind Co Ltd A pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide.
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
US6087324A (en) 1993-06-24 2000-07-11 Takeda Chemical Industries, Ltd. Sustained-release preparation
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
CA2224381A1 (en) 1995-06-27 1997-01-16 Takeda Chemical Industries, Ltd. Method of producing sustained-release preparation
TW448055B (en) 1995-09-04 2001-08-01 Takeda Chemical Industries Ltd Method of production of sustained-release preparation
JP2909418B2 (ja) 1995-09-18 1999-06-23 株式会社資生堂 薬物の遅延放出型マイクロスフイア
US5980945A (en) 1996-01-16 1999-11-09 Societe De Conseils De Recherches Et D'applications Scientifique S.A. Sustained release drug formulations
US6264970B1 (en) 1996-06-26 2001-07-24 Takeda Chemical Industries, Ltd. Sustained-release preparation
US6419961B1 (en) 1996-08-29 2002-07-16 Takeda Chemical Industries, Ltd. Sustained release microcapsules of a bioactive substance and a biodegradable polymer
CA2217134A1 (en) 1996-10-09 1998-04-09 Sumitomo Pharmaceuticals Co., Ltd. Sustained release formulation
CA2219698C (en) 1996-10-31 2007-09-04 Takeda Chemical Industries, Ltd. Sustained-release preparation
KR20000057693A (ko) 1996-12-20 2000-09-25 다케다 야쿠힌 고교 가부시키가이샤 지효성 제제의 제조 방법
US5891474A (en) 1997-01-29 1999-04-06 Poli Industria Chimica, S.P.A. Time-specific controlled release dosage formulations and method of preparing same
US6613358B2 (en) 1998-03-18 2003-09-02 Theodore W. Randolph Sustained-release composition including amorphous polymer
KR19990085365A (ko) 1998-05-16 1999-12-06 허영섭 지속적으로 약물 조절방출이 가능한 생분해성 고분자 미립구 및그 제조방법
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US7674907B2 (en) 2004-07-23 2010-03-09 Amgen Inc. Furanopyridine derivatives and methods of use
AU2006210787C1 (en) 2005-02-02 2013-01-17 Nexgenix Pharmaceuticals, L.L.C. Local treatment of neurofibromas
UA95244C2 (ru) * 2005-06-22 2011-07-25 Плексикон, Инк. Соединения и способ модулирования активности киназ, и показания для их применения
GB0601962D0 (en) * 2006-01-31 2006-03-15 Ucb Sa Therapeutic agents
GB0616214D0 (en) 2006-08-15 2006-09-27 Ucb Sa Therapeutic Agents
KR101428116B1 (ko) 2006-08-21 2014-08-07 제넨테크, 인크. 아자-벤조푸라닐 화합물 및 사용 방법
EP2069359B1 (en) 2006-08-21 2014-11-12 Genentech, Inc. Aza-benzothiophenyl compounds and methods of use
US7943659B2 (en) 2006-10-31 2011-05-17 Takeda Pharmaceutical Company Limited MAPK/ERK kinase inhibitors
PL2099796T3 (pl) * 2006-11-30 2011-10-31 Genentech Inc Związki azaindolilowe i sposoby ich zastosowania
WO2008148034A1 (en) * 2007-05-25 2008-12-04 Takeda Pharmaceutical Company Limited Mapk/erk kinase inhibitors
CA2708176A1 (en) 2007-12-21 2009-07-02 Genentech, Inc. Azaindolizines and methods of use
GB0801081D0 (en) 2008-01-21 2008-02-27 Ucb Pharma Sa Therapeutic agents
EP2240494B1 (en) 2008-01-21 2016-03-30 UCB Biopharma SPRL Thieno-pyridine derivatives as mek inhibitors
GB0801080D0 (en) 2008-01-21 2008-02-27 Ucb Pharma Sa Therapeutic agents
GB0811304D0 (en) 2008-06-19 2008-07-30 Ucb Pharma Sa Therapeutic agents
US8450344B2 (en) * 2008-07-25 2013-05-28 Aerie Pharmaceuticals, Inc. Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds
WO2012040636A2 (en) 2010-09-24 2012-03-29 The Broad Institute, Inc. Compounds and methods for treating diseases mediated by protease activated receptors
GB201104267D0 (en) 2011-03-14 2011-04-27 Cancer Rec Tech Ltd Pyrrolopyridineamino derivatives
US9357781B2 (en) 2013-05-03 2016-06-07 Inscent, Inc. Honeybee repellents and uses thereof
CN105384754B (zh) 2014-09-02 2018-04-20 上海科州药物研发有限公司 作为蛋白激酶抑制剂的杂环类化合物及其制备方法和用途
EP3624796B1 (en) 2017-05-19 2025-03-19 NFlection Therapeutics, Inc. Pyrrolopyridine-aniline compounds for treatment of dermal disorders

Also Published As

Publication number Publication date
WO2018213810A1 (en) 2018-11-22
MX389965B (es) 2025-03-20
PT3624796T (pt) 2025-06-02
CN111065393B (zh) 2023-08-18
JP2020520995A (ja) 2020-07-16
US11161845B2 (en) 2021-11-02
MA49141A (fr) 2020-03-25
US20200165243A1 (en) 2020-05-28
US20250034137A1 (en) 2025-01-30
KR102642411B1 (ko) 2024-02-28
AU2018270295A1 (en) 2019-12-05
MX2022001697A (es) 2022-04-07
AU2018270295B2 (en) 2022-03-03
US12428418B2 (en) 2025-09-30
FI3624796T3 (fi) 2025-06-11
CN111065393A (zh) 2020-04-24
KR20200013239A (ko) 2020-02-06
US12065439B2 (en) 2024-08-20
EP3624796B1 (en) 2025-03-19
PL3624796T3 (pl) 2025-06-30
EP3624796A1 (en) 2020-03-25
JP7212956B2 (ja) 2023-01-26
DK3624796T3 (da) 2025-06-02
US20220033399A1 (en) 2022-02-03
ES3030506T3 (en) 2025-06-30
IL270752A (en) 2020-01-30
IL270752B (en) 2022-06-01
CA3063536A1 (en) 2018-11-22

Similar Documents

Publication Publication Date Title
MX2022001697A (es) Compuestos de pirrolopiridina-anilina para el tratamiento de trastornos dermicos.
MX2023001876A (es) Derivados de rapamicina.
ECSP20033467A (es) Compuestos macrocíclicos para tratar enfermedades
MX2022012313A (es) Oxisteroles y metodos de uso de los mismos.
MX2019006739A (es) Esteroides neuroactivos sustituidos con 19-alcoxi-17, profarmacos de los mismos, y metodos de tratamiento usando los mismos.
DOP2019000030A (es) Inhibidores de cdk2/4/6
SV2016005153A (es) Compuestos y composiciones como inhibidores de la mek
DOP2018000257A (es) Piridinas sustituidas con heteroarilo y métodos de uso
CL2018003681A1 (es) Derivados de ácido borónico y usos terapéuticos de los mismos
DOP2014000204A (es) Compuestos de heterociclilo como inhibidores de mek
MX2018005890A (es) Composiciones para tratar atrofia muscular espinal.
CR20160119A (es) Nuevos compuestos y sus composiciones farmacéuticas para el tratamiento de la fibrosis quística
UY37435A (es) Pirrolidinas sustituidas y métodos para usarlas
MX2019004685A (es) Derivados de 6,7,8,9-tetrahidro-3h-pirazolo[4,3f] isoquinolina utiles en el tratamiento del cancer.
MX2019003724A (es) Oxisteroles sustituidos en c7 y metodos de uso de los mismos.
CU20180152A7 (es) Pirimidin-2-ilamino-1h-pirazoles útiles como inhibidores de lrrk2
DOP2016000140A (es) Inhibidores de syk
DOP2015000241A (es) Compuestos de biaril-amida como inhibidores de cinasa
MX2016014547A (es) Compuestos para tratar atrofia muscular espinal.
CR20150472A (es) USO DE DERIVADOS DE PIRAZOLOPIRIMIDINA PARA EL TRATAMIENTO DE TRANSTORNOS RELACIONADOS CON LA PI3Kd
ECSP22038478A (es) Heteroaril bifenil amidas para el tratamiento de enfermedades relacionadas con el ligando pd-l1
CR20150378A (es) Compuestos tetracíclicos sustituidos con heterociclo y métodos de uso de los mismos para el tratamiento de enfermedades víricas
ECSP14013215A (es) Compuestos novedosos
ECSP22038509A (es) Aminas de heteroaril-bifenilo para el tratamiento de enfermedades pd-l1
UY36702A (es) Piridinas sustituidas y métodos de uso